WildBilly:
"...The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long...."
http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-prices
"...An estimated 3.2 million persons in the United States have chronic Hepatitis C virus infection. Most people do not know they are infected because they don’t look or feel sick...."
http://www.cdc.gov/hepatitis/c/cfaq.htm
Good luck and GOD bless,
George
"...The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long...."
http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-prices
"...An estimated 3.2 million persons in the United States have chronic Hepatitis C virus infection. Most people do not know they are infected because they don’t look or feel sick...."
http://www.cdc.gov/hepatitis/c/cfaq.htm
Good luck and GOD bless,
George
Recent BNTC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 12:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:09:20 PM
- Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 05/14/2026 12:00:00 PM
- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/20/2026 08:03:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 01:09:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 01:07:48 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/11/2026 05:15:29 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/30/2026 09:02:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2025 09:19:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2025 10:27:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:37:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:36:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:35:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:31:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 10:05:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/12/2025 11:06:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:29:10 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2025 02:26:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/05/2025 10:17:07 PM
- Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy • IH Market News • 11/03/2025 02:35:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:11:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/14/2025 09:00:08 PM
